Abrham Mulugeta Shares Insights on Tranexamic Acid: Exploring the WHO WOMAN Trial
Abrham Mulugeta, Gynecologist at Tercha General Hospital, shared on LinkedIn:
”Drug review Tranexamic Acid (TXA)
Tranexamic Acid (TXA): Life-Saving Antifibrinolytic in Postpartum Hemorrhage (PPH)
TXA is a synthetic lysine analogue that inhibits fibrinolysis — stabilizing blood clots when every minute counts.
Mechanism:
Inhibits plasminogen activation → prevents fibrin degradation → promotes stable clot formation.
Dose (as per WHO and WOMAN trial):
1 g IV over 10 min, ideally within 3 hours of birth.
Repeat once after 30 min if bleeding continues or restarts.
Indicated for:
Treatment of postpartum hemorrhage (PPH) after vaginal or cesarean delivery.
Other indications according to local guidlines.
Evidence:
WOMAN Trial (Lancet 2017)
> 20 000+ women
→ Early TXA (≤3 h) ↓ maternal death due to bleeding by ~30 %.
Side effects:
Nausea, vomiting, dizziness
Rare: thromboembolic events → use cautiously in patients with active thrombosis
Key akeaway:
TXA reduces maternal mortality when given early alongside standard PPH management (uterotonics, IV fluids, surgical measures).
Timing matters — “The sooner, the stronger the benefit.”’
Stay updated with Hemostasis Today.
-
Nov 5, 2025, 08:30Claire Auditeau: Thrilled to Share a Major Milestone From My PhD Journey!
-
Nov 5, 2025, 06:51Petros Gatsios Explains Why Europe Must Become Self-Sufficient in Maintaining Its Plasma Supply
-
Nov 5, 2025, 04:08Omid Seidizadeh: Pleased to Announce the Establishment of EAHAD Working Group on VWD
-
Nov 5, 2025, 03:54Marilena Vrana: ''Plasma Powers Possibility'' Continues to Resonate Far Beyond an Awareness Week
-
Nov 5, 2025, 03:30Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 4, 2025, 06:37AI Meets Cardiology Guidelines․ Our JACC Study Is Live
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!